Filing Details

Accession Number:
0001225208-17-002838
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-02-10 18:23:39
Reporting Period:
2017-02-08
Filing Date:
2017-02-10
Accepted Time:
2017-02-10 18:23:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
9892 Bard C R Inc BCR Surgical & Medical Instruments & Apparatus (3841) 221454160
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1580664 P John Groetelaars C/O C. R. Bard, Inc.
730 Central Avenue
Murray Hill NJ 07974
Group President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-02-08 8,223 $0.00 24,777 No 4 A Direct
Common Stock Acquisiton 2017-02-08 2,795 $0.00 27,572 No 4 A Direct
Common Stock Acquisiton 2017-02-08 2,308 $235.49 29,880 No 4 A Direct
Common Stock Acquisiton 2017-02-08 988 $164.84 30,868 No 4 A Direct
Common Stock Disposition 2017-02-08 4,116 $236.68 26,752 No 4 F Direct
Common Stock Disposition 2017-02-09 5,504 $239.66 21,248 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Direct
No 4 A Direct
No 4 A Direct
No 4 F Direct
No 4 S Direct
Footnotes
  1. Represents common shares acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated).
  2. Represents common shares acquired upon satisfaction of performance criteria underlying the award of restricted stock units under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated), 50% of which vest immediately and the remaining 50% vest in two equal annual installments on February 8, 2018 and February 8, 2019.
  3. Restricted stock units acquired through deferral of compensation under the Company's Management Stock Purchase Program.
  4. Shares withheld to pay taxes upon vesting of performance-based restricted stock units granted under the 2012 Long Term Incentive Plan of C. R. Bard, Inc. (as Amended and Restated).
  5. Sales are pursuant to a previously disclosed 10b5-1 plan.
  6. Represents the weighted average sales price for price increments ranging from $239.39 to $239.82. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4.